CALGARY, March 1, 2016 /CNW/ - Resverlogix Corp. (the "Corporation") (TSX:RVX) today announced it will be hosting a corporate update via webcast on Friday, March 4, 2016 at 11:00 am MT / 1:00 pm ET. Featured company presenters will be Mr. Donald McCaffrey, president and chief executive officer and Dr. Michael Sweeney, senior vice president of clinical development.
To join the webcast, please visit: http://services.choruscall.ca/links/resverlogix20160304.html
To call-in please dial:
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL). Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog and via Twitter @Resverlogix_RVX https://twitter.com/resverlogix_rvx.
Donald J. McCaffrey
President and Chief Executive Officer
Director of Investor Relations & Corporate Communications
SOURCE Resverlogix Corp.